Ergoteles’s Q32 Bio QTTB Stock Holding History

Ergoteles’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,605	Closed	-$59.1K	–	1823
2022 Q4	$59.1K	Sell	2,605 -3,444	-57%	-$91.4K	﹤0.01%	1279
2022 Q3	$175K	Sell	6,049 -4,690	-44%	-$191K	0.01%	1229
2022 Q2	$381K	Buy	+10,739	New	+$367K	0.01%	983

Other funds holding QTTB

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Ergoteles's QTTB Position: Q1 2023 in Review

Ergoteles sold out of Q32 Bio (QTTB) in Q1 2023, closing a stake of 2,605 shares — an estimated $59.1K sold.

Ergoteles first reported a position in QTTB in Q2 2022 and held it in 3 quarters. The position peaked at $381K in Q2 2022. 62 funds tracked by Wall St. Rank hold QTTB as of Q1 2023.

Ergoteles reported no remaining Q32 Bio position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 2,605 Q32 Bio shares in Q1 2023, an estimated $59.1K.
Ergoteles first reported a position in Q32 Bio in Q2 2022 and held it in 3 quarters.
Ergoteles's Q32 Bio position peaked at $381K in Q2 2022.
62 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.